{"id":752290,"date":"2023-04-27T17:10:01","date_gmt":"2023-04-27T21:10:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-announce-first-quarter-results-on-may-4-2023\/"},"modified":"2023-04-27T17:10:01","modified_gmt":"2023-04-27T21:10:01","slug":"aligos-therapeutics-to-announce-first-quarter-results-on-may-4-2023","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-announce-first-quarter-results-on-may-4-2023\/","title":{"rendered":"Aligos Therapeutics to Announce First Quarter Results on May 4, 2023"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SOUTH SAN FRANCISCO, Calif., April  27, 2023  (GLOBE NEWSWIRE) &#8212; Aligos Therapeutics, Inc. (Nasdaq: ALGS, \u201cAligos\u201d, the \u201cCompany\u201d), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will report the Company\u2019s first quarter 2023 financial results on Thursday, May 4, 2023, after the close of the U.S. financial markets.<\/p>\n<p>\n        <strong>About Aligos<\/strong><br \/>\n        <br \/>Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of liver diseases and viral infections. Aligos\u2019 strategy is to harness the deep expertise and decades of drug development experience its team has in liver and viral diseases to discover and develop potentially best in class therapeutics for nonalcoholic steatohepatitis (NASH) and viruses with high unmet medical need such as coronaviruses and chronic hepatitis B (CHB).<\/p>\n<p>\n        <strong>Forward-Looking Statement <\/strong><br \/>\n        <br \/>This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered \u201cforward-looking statements\u201d. Forward-looking statements are typically, but not always, identified by the use of words such as \u201cmay,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201cbelieve,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cestimate,\u201d \u201cexpect,\u201d and other similar terminology indicating future results. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos\u2019 clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Aligos\u2019 ability to successfully establish, protect and defend its intellectual property, and other matters that could affect the sufficiency of Aligos\u2019 capital resources to fund operations. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos\u2019 Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 9, 2023 and its future periodic reports to be filed with or submitted to the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.<\/p>\n<p>\n        <strong>Media Contact<\/strong><br \/>\n        <br \/>Amy Jobe, Ph.D.<br \/>LifeSci Communications<br \/>+1 315 879 8192<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BTCvmtKgPizF5yIgY6oNjJ711laeqse5esBTJ1t4DPmbLRNVfvXYPCTOgy6NLnFE8TTOCgIdcQNMhzLyAmaMXiIUKn0gAf68bsCVKHihfpM=\" rel=\"nofollow noopener\" target=\"_blank\">ajobe@lifescicomms.com<\/a><\/p>\n<p>\n        <strong>Investor Contact<\/strong><br \/>\n        <br \/>Corey Davis, Ph.D.<br \/>LifeSci Advisors<br \/>+1 212 915 2577<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Qq7_Y4yVXAxoIljKliBJoD1YREgUkSWOgP0pC9SsXAtzweQMj329p0CtODofemCTMSxy5i-oAQxQK7KBuW1cqBhw7cuvoYJG-dpSuwDEfFjpQAI9cYcIYFDew8rS2mZa\" rel=\"nofollow noopener\" target=\"_blank\">cdavis@lifesciadvisors.com<\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNzQ5OCM1NTYyNjU0IzIyMDM5MTY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZmM3ZmVkYzUtMjRlMi00Yzc5LWEyYzItMWNlYWI1ZDE0ODgzLTEyMTU0Njk=\/tiny\/Aligos-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif., April 27, 2023 (GLOBE NEWSWIRE) &#8212; Aligos Therapeutics, Inc. (Nasdaq: ALGS, \u201cAligos\u201d, the \u201cCompany\u201d), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will report the Company\u2019s first quarter 2023 financial results on Thursday, May 4, 2023, after the close of the U.S. financial markets. About Aligos Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of liver diseases and viral infections. Aligos\u2019 strategy is to harness the deep expertise and decades of drug development experience its team has in liver and viral diseases to &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-announce-first-quarter-results-on-may-4-2023\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Aligos Therapeutics to Announce First Quarter Results on May 4, 2023&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-752290","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aligos Therapeutics to Announce First Quarter Results on May 4, 2023 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-announce-first-quarter-results-on-may-4-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aligos Therapeutics to Announce First Quarter Results on May 4, 2023 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., April 27, 2023 (GLOBE NEWSWIRE) &#8212; Aligos Therapeutics, Inc. (Nasdaq: ALGS, \u201cAligos\u201d, the \u201cCompany\u201d), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will report the Company\u2019s first quarter 2023 financial results on Thursday, May 4, 2023, after the close of the U.S. financial markets. About Aligos Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of liver diseases and viral infections. Aligos\u2019 strategy is to harness the deep expertise and decades of drug development experience its team has in liver and viral diseases to &hellip; Continue reading &quot;Aligos Therapeutics to Announce First Quarter Results on May 4, 2023&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-announce-first-quarter-results-on-may-4-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-27T21:10:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNzQ5OCM1NTYyNjU0IzIyMDM5MTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-to-announce-first-quarter-results-on-may-4-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-to-announce-first-quarter-results-on-may-4-2023\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Aligos Therapeutics to Announce First Quarter Results on May 4, 2023\",\"datePublished\":\"2023-04-27T21:10:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-to-announce-first-quarter-results-on-may-4-2023\\\/\"},\"wordCount\":442,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-to-announce-first-quarter-results-on-may-4-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNzQ5OCM1NTYyNjU0IzIyMDM5MTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-to-announce-first-quarter-results-on-may-4-2023\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-to-announce-first-quarter-results-on-may-4-2023\\\/\",\"name\":\"Aligos Therapeutics to Announce First Quarter Results on May 4, 2023 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-to-announce-first-quarter-results-on-may-4-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-to-announce-first-quarter-results-on-may-4-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNzQ5OCM1NTYyNjU0IzIyMDM5MTY=\",\"datePublished\":\"2023-04-27T21:10:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-to-announce-first-quarter-results-on-may-4-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-to-announce-first-quarter-results-on-may-4-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-to-announce-first-quarter-results-on-may-4-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNzQ5OCM1NTYyNjU0IzIyMDM5MTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNzQ5OCM1NTYyNjU0IzIyMDM5MTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-to-announce-first-quarter-results-on-may-4-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aligos Therapeutics to Announce First Quarter Results on May 4, 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aligos Therapeutics to Announce First Quarter Results on May 4, 2023 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-announce-first-quarter-results-on-may-4-2023\/","og_locale":"en_US","og_type":"article","og_title":"Aligos Therapeutics to Announce First Quarter Results on May 4, 2023 - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., April 27, 2023 (GLOBE NEWSWIRE) &#8212; Aligos Therapeutics, Inc. (Nasdaq: ALGS, \u201cAligos\u201d, the \u201cCompany\u201d), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will report the Company\u2019s first quarter 2023 financial results on Thursday, May 4, 2023, after the close of the U.S. financial markets. About Aligos Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of liver diseases and viral infections. Aligos\u2019 strategy is to harness the deep expertise and decades of drug development experience its team has in liver and viral diseases to &hellip; Continue reading \"Aligos Therapeutics to Announce First Quarter Results on May 4, 2023\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-announce-first-quarter-results-on-may-4-2023\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-27T21:10:01+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNzQ5OCM1NTYyNjU0IzIyMDM5MTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-announce-first-quarter-results-on-may-4-2023\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-announce-first-quarter-results-on-may-4-2023\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Aligos Therapeutics to Announce First Quarter Results on May 4, 2023","datePublished":"2023-04-27T21:10:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-announce-first-quarter-results-on-may-4-2023\/"},"wordCount":442,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-announce-first-quarter-results-on-may-4-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNzQ5OCM1NTYyNjU0IzIyMDM5MTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-announce-first-quarter-results-on-may-4-2023\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-announce-first-quarter-results-on-may-4-2023\/","name":"Aligos Therapeutics to Announce First Quarter Results on May 4, 2023 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-announce-first-quarter-results-on-may-4-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-announce-first-quarter-results-on-may-4-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNzQ5OCM1NTYyNjU0IzIyMDM5MTY=","datePublished":"2023-04-27T21:10:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-announce-first-quarter-results-on-may-4-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-announce-first-quarter-results-on-may-4-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-announce-first-quarter-results-on-may-4-2023\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNzQ5OCM1NTYyNjU0IzIyMDM5MTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNzQ5OCM1NTYyNjU0IzIyMDM5MTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-announce-first-quarter-results-on-may-4-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Aligos Therapeutics to Announce First Quarter Results on May 4, 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/752290","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=752290"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/752290\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=752290"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=752290"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=752290"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}